Jade Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.53M.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $45.00K.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $247.00K.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $22.00K, a 76.84% decline year-over-year.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $88.00K, a 94.07% decline from fiscal 2024.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.48M, a 50.51% increase from fiscal 2023.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $986.00K, a 59.81% increase from fiscal 2022.
- Jade Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $617.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.53M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $45.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $88.00K 10-K · filed 2026-03-06 | |
| 2024-12-31 | $247.00K derived: 10-K 12 month − 3 quarters · filed 2025-03-27 | $1.48M 10-K · filed 2025-03-27 |
| 2024-09-30 | $22.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $511.00K 10-Q · filed 2024-11-12 | |
| 2024-03-31 | $704.00K 10-Q · filed 2025-04-25 | |
| 2023-12-31 | $986.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $95.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $333.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $223.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $617.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $160.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $14.00K 10-Q · filed 2023-11-13 | |
| 2020-12-31 | $5.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $5.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |